NT5E (PM-1015 Biosimilar) Recombinant Monoclonal Antibody
-
貨號(hào):CSB-RA723415MB12HU
-
規(guī)格:¥83486
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:NT5E(PM-1015 Biosimilar Antibody)重組單克隆抗體是一款專為科研用途開發(fā)的生物試劑,能夠特異性識(shí)別并結(jié)合NT5E(5'-核苷酸酶)蛋白。該抗體通過基因工程技術(shù)在哺乳動(dòng)物細(xì)胞中表達(dá),經(jīng)過嚴(yán)格的純化工藝和質(zhì)量控制,確保具備高純度、高親和力和批次間一致性,為相關(guān)研究提供可靠的工具支持。 NT5E作為一種膜結(jié)合型糖蛋白,在核苷酸代謝、細(xì)胞外腺苷生成及免疫調(diào)節(jié)等生理過程中發(fā)揮關(guān)鍵作用。研究表明,其異常表達(dá)與腫瘤微環(huán)境調(diào)控、炎癥反應(yīng)及免疫逃逸等多種病理機(jī)制密切相關(guān)。本抗體可廣泛應(yīng)用于某些實(shí)驗(yàn),助力解析NT5E在生理與病理狀態(tài)下的功能機(jī)制,推動(dòng)腫瘤免疫學(xué)、代謝調(diào)控及相關(guān)疾病領(lǐng)域的基礎(chǔ)研究。 該試劑僅限實(shí)驗(yàn)室研究使用,不適用于臨床診斷或治療。產(chǎn)品提供詳細(xì)的使用說明書,包含最適稀釋比例、孵育條件及實(shí)驗(yàn)案例參考,便于科研人員快速建立實(shí)驗(yàn)體系。通過特異性靶向NT5E,本抗體為探索其生物學(xué)功能及潛在的研究應(yīng)用提供了有力支持,有望為相關(guān)領(lǐng)域的科學(xué)發(fā)現(xiàn)奠定基礎(chǔ)。
-
Uniprot No.:
-
基因名:
-
別名:PM 1015 research-grade biosimilar; PM-1015 research-grade biosimilar ;NT5E antibody; NT5 antibody; NTE antibody; 5'-nucleotidase antibody; 5'-NT antibody; EC 3.1.3.35 antibody; EC 3.1.3.5 antibody; EC 3.1.3.89 antibody; EC 3.1.3.91 antibody; EC 3.1.3.99 antibody; 5'-deoxynucleotidase antibody; Ecto-5'-nucleotidase antibody; IMP-specific 5'-nucleotidase antibody; Thymidylate 5'-phosphatase antibody; CD antigen CD73 antibody
-
反應(yīng)種屬:Human
-
免疫原:Recombinant Human NT5E protein
-
免疫原種屬:Homo sapiens (Human)
-
標(biāo)記方式:Non-conjugated
-
克隆類型:Monoclonal
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:0.01M PBS,pH7.4
-
產(chǎn)品提供形式:Liquid
-
應(yīng)用說明:Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲(chǔ)存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:3-4 weeks
-
用途:It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能:Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.
-
基因功能參考文獻(xiàn):
- Changes in the local expression and activity of CD39 and CD73 in calcified valves suggest their potential role in calcific aortic valve disease. PMID: 30056298
- High expression of NT5E is associated with Prostate Cancer. PMID: 29916747
- Case Report: identify novel mutations in the NT5E gene in patient with calcification of joints and arteries. PMID: 28825389
- High CD73 expression is associated with breast cancer. PMID: 29047106
- High CD73 expression is associated with neoplasms. PMID: 29514610
- NT5E-targeting miRNAs (miR-30b and miR-340) function as tumor suppressors PMID: 29155108
- soluble CD73 might be used as serologic prognostic biomarker in patients with metastatic melanoma patients. PMID: 29202855
- High CD73 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity. PMID: 29367423
- analysis of how inhibitors block human CD73 and block efficiently its enzymatic function in the low micromolar range through a non-competitive inhibition mechanism PMID: 29377887
- The Ecto-5'nucleotidase, together with alkaline phosphatase, also expressed apically in oviductal epithelium, complete the hydrolysis sequence by dephosphorylating AMP to adenosine. PMID: 29273916
- this paper shows that simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro PMID: 28389406
- high levels of CD73 are significantly associated with reduced overall survival in patients with head and neck squamous cell carcinoma PMID: 27557512
- Studied role of miR-30a in colorectal cancer(CRC). Found miR-30a is downregulated in CRC, and it inhibits cell proliferation in CRC by reducing expression of CD73. PMID: 28464916
- we demonstrated the existence of CSCs in both cultured ccRCC cell line and tissues, and CD73 as a cell-surface biomarker for ccRCC CSC-like cells. PMID: 28404888
- Induction of ecto-5'-nucleotidase/CD73 by radiation contributes to the radiosensitivity of T24 urinary bladder cancer cell line. PMID: 29305710
- Report prognostic impact of CD73 expression in non-small lung cancers. PMID: 28060732
- Data show that MiR-422a and its target CD73 are involved in early loco(regional) recurrence of head and neck squamous cell carcinoma (HNSCC) tumors and are targets for personalized medicine. PMID: 27281619
- HPV+ cervical cancer cells express higher levels of CD73 than HPV- cells, and this expression is associated with the production of larger amounts of adenosine, as well as a stronger inhibition of proliferation, activation, and cytotoxic activity of CD8+ T cells via interaction with A2A adenosine receptor PMID: 28950987
- High CD73 expression is associated with Melanoma Metastasis. PMID: 28652244
- Hippocampal astrogliosis observed in medial temporal lobe epilepsy patients was accompanied by a proportionate increase in A2A receptor and ecto-5'-nucleotidase/CD73 immunoreactivities. PMID: 27650530
- High CD73 expression is associated with cervical cancer. PMID: 28202050
- Endogenous Plastic Somatic (ePS) cells in a latent state, i.e. lacking SOX2, OCT3/4 and NANOG (SON) expression, in non-diseased breast specimens through immunohistochemical analysis of previously identified ePS-specific biomarkers (CD73(+), EpCAM(+) and CD90(-)). PMID: 27705752
- Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression. PMID: 28193736
- CD73 polymorphisms play a role in calciphylaxis development in dialysis patients. PMID: 28212442
- CD73 expression is upregulated in NSCLC and is correlated with a decrease in miR-30a-5p expression. PMID: 28158983
- This study found that in septic critically ill patients the soluble CD73 levels were generally low and showed a further decrease from 0h to 24h. Moreover, the sCD73 levels were higher in acute kidney injury (AKI) versus non-AKI patients and in non-survivors with severe sepsis than in survivors, but were not independently associated either with the development of AKI or 90-day mortal PMID: 27732656
- concluded that CD39 and CD73 are molecular targets for the development of drugs for ALF patients care PMID: 27899277
- Genetic polymorphism of NT5E may contribute to the pathogenesis of calcific aortic valve disease. PMID: 27906615
- Oxidized low density lipoproteins modulate CD39 and CD73 activity in the endothelium. PMID: 27906627
- CD73 may play an important role in breast cancer stem cells. PMID: 27670764
- This study aimed to investigate the activities of purinergic system ecto-enzymes present on the platelet surface as well as CD39 and CD73 expressions on platelets of sickle cell anemia treated patients. PMID: 27044834
- Aim of the present study was to investigate the role of CD73 in glioma blood vessels; results found that the expression of CD73 in glioma vascular cells is significantly decreased, and this reduction may down-regulate the expression of brain microvascular endothelial tight junction-related proteins PMID: 26884147
- These results provide a finely mapped epitope that can be targeted for selective, potent, and non-competitive inhibition of CD73, as well as establish a strategy for inhibiting enzymes that function in both membrane-bound and soluble states. PMID: 26854859
- CD73 promotes the growth of human colorectal cancer cells through EGFR and the b-catenin/cyclin D1 signaling pathway. CD73 may be used as a valuable biomarker of colorectal cancer. PMID: 26708311
- Our study revealed that CD73 is an independent prognostic factor in prostate cancer. PMID: 26253870
- The NT5E gene is involved in both intrinsic and acquired resistance to platinum-based drugs in ovarian cancer. [meta-analysis] PMID: 26629888
- CD73 expression was significantly correlated with the invasion into adjacent organs. PMID: 26691441
- report on a Chinese family with CALJA and novel compound heterozygous mutations (c.1360G>A (p.Gly454Arg) and c.1387C>T (p.Arg463X)) in NT5E PMID: 26178434
- findings reveal that CD73-generated adenosine promotes epithelial integrity and suggest why loss of CD73 in endometrial cancer allows for tumor progression PMID: 26642367
- CD73 activity from any host cell type is not required for the monocyte/macrophage polarization in the peritoneum towards a pro- or an anti-inflammatory phenotype in vivo PMID: 26258883
- these data suggest a possible role for CD73 and A2A in inflammation observed in patients with T2D and obesity mediated via apoptosis. PMID: 25770019
- This study highlights a role for CD73 as a prognostic marker of patient survival and also as a candidate therapeutic target in high-grade serous ovarian cancers. PMID: 26363007
- role of CD73 and CD39 ectonucleotidases in T cell differentiation PMID: 26226423
- Expression of NPP1 and 5'-nucleotidase by valve interstitial cells promotes the mineralization of the aortic valve through A2aR and a cAMP/PKA/CREB pathway. PMID: 25644539
- Although upregulated CD73 expression in tumor cells correlates with a poor prognosis in patients with rectal adenocarcinoma, the combination of CD73 expression in malignant epithelial cells and tumor stroma may have a better prognostic value PMID: 25677906
- rs9444348 heterozygosity is associated with increased risk of post-traumatic epilepsy development after brain injury. PMID: 26040919
- Species-specific CD73 regulation, with potential significance to cancer, fibrosis, and other diseases characterized by changes in CD73 expression and function. PMID: 25298403
- The Nt5e(-/-) targeted mutant mice recapitulate some, but not all, features of ACDC and serve as a model system to study pharmacologic interventions for ectopic mineralization. PMID: 25486201
- CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature. PMID: 25402681
- It decompose ATP and produce adenosine, which regulates immunity via adenosine receptor. PMID: 25675814
顯示更多
收起更多
-
相關(guān)疾?。?/div>Calcification of joints and arteries (CALJA)亞細(xì)胞定位:Cell membrane; Lipid-anchor, GPI-anchor.蛋白家族:5'-nucleotidase family數(shù)據(jù)庫鏈接:
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-















